Nephrol Dial Transplant (2003) 18: 2399-2404
© 2003 European Renal Association-European Dialysis and Transplant Association
Original Article
Renal transplantation in patients with primary immunoglobulin A nephropathy
1Division of Nephrology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong and 2Institute for International Health, University of Sydney, New South Wales, Australia
Correspondence and offprint requests to: Professor K. N. Lai, Division of Nephrology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Hong Kong. Email: knlai{at}hkucc.hku.hk
Background. Opinions on the clinical course and outcome of renal transplantation in patients with primary immunoglobulin A nephropathy (IgAN) have been controversial.
Methods. We conducted a retrospective single-centre study on 542 kidney transplant recipients over the period 1984–2001. Long-term outcome and factors affecting recurrence in recipients with primary IgAN were analysed.
Results. Seventy-five patients (13.8%) had biopsy-proven IgAN as the cause of renal failure, and their mean duration of follow-up after transplantation was 100 ± 5.8 months. Fourteen (18.7%) of the 75 patients had biopsy-proven recurrent IgAN, diagnosed at 67.7 ± 11 months after transplantation. The risk of recurrence was not associated with HLA DR4 or B35. Graft failure occurred in five (35.7%) of the 14 patients: three due to IgAN and two due to chronic rejection. Three (4.9%) of the 61 patients without recurrent IgAN had graft failure, all due to chronic rejection. Graft survival was similar between living-related and cadaveric/living-unrelated patients (12-year graft survival, 88 and 72%, respectively, P = 0.616). Renal allograft survival within the first 12 years was better in patients with primary IgAN compared with those with other primary diseases (80 vs 51%, P = 0.001). Thereafter, IgAN patients showed an inferior graft survival (74 vs 97% in non-IgAN patients, P = 0.001).
Conclusions. Our data suggested that around one-fifth of patients with primary IgAN developed recurrence by 5 years after transplantation. Recurrent IgA nephropathy in allografts runs an indolent course with favourable outcome in the first 12 years. However, the contribution of recurrent disease to graft loss becomes more significant on long-term follow up.
Keywords: graft survival; IgA nephropathy; outcome; recurrence; renal transplantation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. E. Courtney, P. T. McNamee, W. E. Nelson, and A. P. Maxwell Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3550 - 3554. [Abstract] [Full Text] [PDF]
|
|